<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Photodynamic therapy (<z:chebi fb="7" ids="53228">PDT</z:chebi>) is a novel technique for local endoscopic treatment of gastrointestinal <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Current photosensitisers for <z:chebi fb="7" ids="53228">PDT</z:chebi> may cause prolonged skin <z:mp ids='MP_0005653'>phototoxicity</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>5-Aminolaevulinic acid (ALA), a precursor of the photosensitiser <z:chebi fb="0" ids="15430">protoporphyrin</z:chebi> IX (<z:chebi fb="0" ids="36159">PpIX</z:chebi>), is more acceptable because of its short half-life and preferential accumulation in mucosa and mucosal <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We have treated 12 patients, median age 73 years (range 55-88) with oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> arising from Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> (two <z:mp ids='MP_0002038'>carcinomas</z:mp>-in-situ, grade 0; 10 <z:mp ids='MP_0002038'>carcinomas</z:mp>, grade 1-11A based on endoluminal ultrasound in two and CT scanning in 10 patients) </plain></SENT>
<SENT sid="4" pm="."><plain>ALA (60 and 75 mg/kg body weight) was given orally in two or five equally divided doses </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:chebi fb="0" ids="36159">PpIX</z:chebi> distribution in stomach, <z:mpath ids='MPATH_458'>normal</z:mpath> oesophagus, Barrett's mucosa and <z:mp ids='MP_0002038'>carcinoma</z:mp> was measured by quantitative fluorescence photometry </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="7" ids="53228">PDT</z:chebi> was performed using laser light (630 nm) delivered via a cylindrical diffuser 4-6 h after the first dose of ALA </plain></SENT>
<SENT sid="7" pm="."><plain>The patients received one to four sessions of <z:chebi fb="7" ids="53228">PDT</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="36159">PpIX</z:chebi> accumulation in the mucosa was two to three times that in the lamina propria </plain></SENT>
<SENT sid="9" pm="."><plain>The differential distribution between carcinomatous and <z:mpath ids='MPATH_458'>normal</z:mpath> oesophageal mucosa was less marked (<z:mp ids='MP_0002038'>carcinoma</z:mp>:<z:mpath ids='MPATH_458'>normal</z:mpath> mucosa ratio = 1.4) </plain></SENT>
<SENT sid="10" pm="."><plain>Higher doses of ALA increased <z:chebi fb="0" ids="36159">PpIX</z:chebi> accumulation in <z:hpo ids='HP_0000001'>all</z:hpo> tissues but did not increase the differential <z:chebi fb="0" ids="36159">PpIX</z:chebi> distribution between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> oesophageal mucosa </plain></SENT>
<SENT sid="11" pm="."><plain>After <z:chebi fb="7" ids="53228">PDT</z:chebi> using ALA (ALA/<z:chebi fb="7" ids="53228">PDT</z:chebi>), <z:hpo ids='HP_0000001'>all</z:hpo> mucosa showed superficial white necrotic changes and the histology confirmed fibrinoid <z:mp ids='MP_0001651'>necrosis</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>One patient with <z:mp ids='MP_0002038'>carcinoma</z:mp>-in-situ had the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> eradicated after one treatment with no recurrence at 28 months </plain></SENT>
<SENT sid="13" pm="."><plain>Another patient with a small T1 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> required four ALA/<z:chebi fb="7" ids="53228">PDT</z:chebi> treatments, and died of other disease after 36 months </plain></SENT>
<SENT sid="14" pm="."><plain>There was no evidence of recurrence </plain></SENT>
<SENT sid="15" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> bulk in the other <z:mp ids='MP_0002038'>carcinomas</z:mp> was not significantly reduced </plain></SENT>
<SENT sid="16" pm="."><plain>ALA/<z:chebi fb="7" ids="53228">PDT</z:chebi> has a potential for the eradication of small <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> but careful patient selection with endoluminal ultrasound is needed when using ALA/<z:chebi fb="7" ids="53228">PDT</z:chebi> to treat <z:e sem="disease" ids="C0546837" disease_type="Neoplastic Process" abbrv="">oesophageal cancer</z:e> </plain></SENT>
</text></document>